Mars Transit in Cancer: Impact on Career and Finance for Zodiac Signs

On September 18, 2026, Mars (Kuja) entered the కర్కాటకం (Cancer) zodiac sign, sparking a significant surge in astrological interest across India. According to reports, Mars will remain in this position for approximately 55 days before transitioning into Leo (Simha) [1]. While Mars is traditionally considered weak in Cancer, the current alignment with Jupiter (Guru) is expected to mitigate negative effects and bring favorable outcomes for several signs.

Key Dates and Planetary Alignments

The transit is divided into two critical phases. First, the general entry into కర్కాటకం on September 18 sets the stage for the next two months. Second, a more specific shift occurs as Mars enters the Pushya nakshatra from September 24 to October 17, 2026 [2]. Because Pushya's presiding deity is Brihaspati (Jupiter), the adverse nature of Mars in this sign is lessened, creating opportunities for growth in professional and financial sectors.

Impact on Career and Finance by Zodiac Sign

Different zodiac signs are expected to experience varying degrees of success during this period. The following table summarizes the reported benefits based on the current transit:

Zodiac Sign	Expected Benefits	Key Focus Area
Cancer (కర్కాటకం)	Unexpected financial gains, completion of pending tasks	Business & Finance
Leo (సింహ రాశి)	Job changes, recovery of old debts, fulfillment of desires	Career & Spirituality
Libra (తులా రాశి)	Promotions, new income streams, academic success	Career Growth
Scorpio (వృశ్చిక రాశి)	New income sources, progress in business and employment	Financial Stability
Aries, Capricorn, Sagittarius, Virgo	Fortune during Pushya nakshatra (Sept 24 – Oct 17)	General Prosperity

Practical Guidance for Readers

For those in కర్కాటకం and other highlighted signs, this period is suggested as an ideal time to restart stalled projects or seek new employment opportunities. However, it is important to note that these predictions are based on traditional astrological beliefs and lack empirical scientific validation. Readers should treat this as general guidance and consult financial or professional advisors for critical life decisions.